{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T02:45:30Z","timestamp":1771641930580,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"American Lymphedema Framework Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Treatment of chronic illness accounts for over 90% of Medicare spending. Chronic lymphedema places 3\u201310 million Americans at risk for recurrent cellulitis. Without convincing predictions of the costs and benefits of lymphedema treatment, insurers are reluctant to fully cover treatment of this common condition. Earlier papers discussed the costs and benefits of the first 5, 7, and 10\u2009years of a lymphedema treatment mandate in Virginia. This paper updates these costs and benefits to 16\u2009years of experience, and includes the impacts of the Patient Protection and Affordable Care Act of 2010 and the transition to ICD-10-CM diagnostic codes in 2015. It provides added confidence that costs of a lymphedema treatment mandate are reasonable, and can result in health insurance contract savings for reduced medical visits and hospitalizations for lymphedema patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Virginia requires annual reporting of the segregated costs of each of its 30 medical mandates. Data on Virginia\u2019s lymphedema treatment mandate for the years 2004 to 2019 have been collected from the series of annual reports. These data include actual lymphedema treatment claims data, utilization data, and claims-based estimates of the premium impact.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The average actual lymphedema claim cost was $2.03 per individual contract and $3.54 per group contract for the years reported, representing 0.05 and 0.08% of average total claims. The estimated premium impact was 0.16\u20130.32% of total average premium for all mandated coverage contracts. While lymphedema claim costs increased 3\u20136% per year over the study period, generally following the rise of health care costs, claim costs as a percent of average contract claims fell at a rate of 1.26\u20131.52% per year over that period. Medical office visits for lymphedema-related services fell from 0.10 to 0.02 visits per year per contract from the beginning to the end of the study period, and hospitalizations for lymphedema or lymphedema-related cellulitis fell to almost zero.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The Virginia data confirmed previous conclusions that the costs of treatment of lymphedema are a small part of a typical health insurance contract, and that treatment of lymphedema by managing swelling results in lower overall medical costs and fewer hospitalizations. This is a potent model for reduction in healthcare costs while improving the quality of care for cancer survivors and others suffering with this chronic progressive condition.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13561-022-00388-6","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T13:03:53Z","timestamp":1658581433000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cost of a lymphedema treatment mandate - 16\u2009years of experience in the Commonwealth of Virginia"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2279-8554","authenticated-orcid":false,"given":"Robert","family":"Weiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,23]]},"reference":[{"key":"388_CR1","volume-title":"\u201cNearly 46m Americans would be unable to afford quality healthcare in an emergency\u201d The Guardian","author":"J Glenza","year":"2021","unstructured":"Glenza J \u201cNearly 46m Americans would be unable to afford quality healthcare in an emergency\u201d The Guardian 2021 https:\/\/www.theguardian.com\/us-news\/2021\/mar\/31\/us-affordable-healthcare-uninsured-underinsured. Accessed 29 Jun 2022."},{"issue":"4","key":"388_CR2","first-page":"174","volume":"28","author":"JR Casley-Smith","year":"1995","unstructured":"Casley-Smith JR. Alterations of untreated lymphedema and its grades over time. Lymphology. 1995;28(4):174\u201385 https:\/\/journals.uair.arizona.edu\/index.php\/lymph\/article\/view\/17523\/17266 Accessed 18 May 2022.","journal-title":"Lymphology"},{"issue":"3","key":"388_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1001\/jama.2016.8825","volume":"316","author":"AB Raff","year":"2016","unstructured":"Raff AB, Kroshinsky D. Cellulitis: a review. JAMA. 2016;316(3):325\u201337. https:\/\/doi.org\/10.1001\/jama.2016.8825 Accessed 17 May 2022.","journal-title":"JAMA"},{"issue":"1","key":"388_CR4","first-page":"56","volume":"62","author":"C St\u00f6berl","year":"1987","unstructured":"St\u00f6berl C, Partsch H. \u201cErysipel und Lymph\u00f6dem \u2013 Ei oder Henne?\u201d [Erysipelas and Lymphedema \u2013 Egg or Hen?]. Z Hautkr. 1987;62(1):56\u201362 Accessed 18 May 2022.","journal-title":"Z Hautkr"},{"issue":"2","key":"388_CR5","first-page":"48","volume":"29","author":"M F\u00f6ldi","year":"1996","unstructured":"F\u00f6ldi M. Prevention of dermatolymphangioadenitis by combined physiotherapy of the swollen arm after treatment for breast cancer. Lymphology. 1996;29(2):48\u20139 Accessed 17 May 2022.","journal-title":"Lymphology"},{"key":"388_CR6","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s100960050478","volume":"19","author":"PCY Woo","year":"2000","unstructured":"Woo PCY, Lum PNL, Wong SSY, et al. Cellulitis complicating Lymphoedema. EJCMID. 2000;19:294\u20137. https:\/\/doi.org\/10.1007\/s100960050478 Accessed 17 May 2022.","journal-title":"EJCMID"},{"key":"388_CR7","volume-title":"Lymph Stasis: Pathophysiology, Diagnosis and Treatment","author":"WL Olszewski","year":"1991","unstructured":"Olszewski WL. Lymph Stasis: Pathophysiology, Diagnosis and Treatment. Boca Raton: CRC Press; 1991."},{"key":"388_CR8","unstructured":"Wittlinger G, Wittlinger H. Textbook of Dr. Vodder\u2019s Manual Lymph Drainage. Heidelberg: Karl F. Haug Verlag; 1978."},{"key":"388_CR9","volume-title":"Lymphoedema Methods of Treatment and Control","author":"M F\u00f6ldi","year":"1991","unstructured":"F\u00f6ldi M, F\u00f6ldi E. Lymphoedema Methods of Treatment and Control. Victoria: Lymphoedema Association of Victoria; 1991."},{"key":"388_CR10","volume-title":"Modern Treatment for Lymphoedema","author":"JR Casley-Smith","year":"1997","unstructured":"Casley-Smith JR, Casley-Smith JR. Modern Treatment for Lymphoedema. Malvern: The Lymphoedema Association of Australia; 1997."},{"issue":"1","key":"388_CR11","first-page":"3","volume":"53","author":"International Society of Lymphology Executive Committee","year":"2020","unstructured":"International Society of Lymphology Executive Committee. The diagnosis and treatment of peripheral lymphedema: 2020 consensus document of the international society of lymphology. Lymphology. 2020;53(1):3\u201319 https:\/\/journals.uair.arizona.edu\/index.php\/lymph\/article\/view\/23775\/22411 Accessed 17 May 2021.","journal-title":"Lymphology"},{"issue":"12","key":"388_CR12","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1002\/cncr.23494","volume":"112","author":"NL Stout Gergich","year":"2008","unstructured":"Stout Gergich NL, Pfalzer LA, McGarvey C, et al. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer. 2008;112(12):2809\u201319. https:\/\/doi.org\/10.1002\/cncr.23494 Accessed 17 May 2022.","journal-title":"Cancer"},{"issue":"1","key":"388_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2522\/ptj.20100167","volume":"92","author":"NL Stout","year":"2012","unstructured":"Stout NL, Pfalzer LA, Springer B, Levy E, McGarvey CL, Danoff JV, et al. Breast cancer-related lymphedema: comparing direct costs of a prospective surveillance model and a traditional model of care. Phys Ther. 2012;92(1):152\u201363. https:\/\/doi.org\/10.2522\/ptj.20100167 Accessed 17 May 2022.","journal-title":"Phys Ther"},{"issue":"6","key":"388_CR14","first-page":"272","volume":"13","author":"HN Mayrovitz","year":"2000","unstructured":"Mayrovitz HN, Sims N, Macdonald J. Assessment of limb volume by manual and automated methods in patients with limb edema or lymphedema. Adv Skin Wound Care. 2000;13(6):272\u20136 Accessed 17 May 2022.","journal-title":"Adv Skin Wound Care"},{"issue":"8 suppl","key":"388_CR15","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1002\/cncr.27473","volume":"118","author":"AL Cheville","year":"2012","unstructured":"Cheville AL, Nyman JA, Pruthi S, Basford JR. Cost considerations regarding the prospective surveillance model for breast cancer survivors. Cancer. 2012;118(8 suppl):2325\u201330 Accessed 17 May 2022.","journal-title":"Cancer"},{"issue":"2","key":"388_CR16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2458\/lymph.4630","volume":"52","author":"HN Mayrovitz","year":"2019","unstructured":"Mayrovitz HN, Arzanova E, Somarriba S, Eisa S. Factors affecting interpretation of tissue dielectric constant (TDC) in assessing breast cancer treatment related lymphedema (BCRL). Lymphology. 2019;52(2):92\u2013102. https:\/\/doi.org\/10.2458\/lymph.4630 Accessed 17 May 2022.","journal-title":"Lymphology"},{"issue":"10","key":"388_CR17","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1080\/13696998.2018.1491008","volume":"21","author":"A Cohen","year":"2018","unstructured":"Cohen A, Gaebler JA, Izhakoff J, et al. US budget impact of increased payer adoption of the Flexitouch advanced pneumatic compression device in lymphedema patients with advanced chronic venous insufficiency and multiple infections. J Med Econ. 2018;21(10):993\u20131000. https:\/\/doi.org\/10.1080\/13696998.2018.1491008 Accessed 17 May 2022.","journal-title":"J Med Econ"},{"issue":"12","key":"388_CR18","doi-asserted-by":"publisher","first-page":"e114597","DOI":"10.1371\/journal.pone.0114597","volume":"9","author":"KM Brayton","year":"2014","unstructured":"Brayton KM, Hirsch AT, O\u2019Brien PJ, Cheville A, Karaca-Mandic P, Rockson SG. Lymphedema prevalence and treatment benefits in cancer: impact of a therapeutic intervention on health outcomes and costs. Plos One. 2014;9(12):e114597. https:\/\/doi.org\/10.1371\/journal.pone.0114597 Accessed 17 May 2022.","journal-title":"Plos One"},{"issue":"6","key":"388_CR19","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/pon.4239","volume":"26","author":"J Boyages","year":"2016","unstructured":"Boyages J, Xu Y, Kalfa S, et al. Financial cost of lymphedema borne by women with breast cancer. Psycho-Oncology. 2016;26(6):849\u201355. https:\/\/doi.org\/10.1002\/pon.4239 Accessed 17 May 2022.","journal-title":"Psycho-Oncology"},{"issue":"4","key":"388_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1001\/archsurg.133.4.452","volume":"133","author":"DSC Ko","year":"1998","unstructured":"Ko DSC, Lerner R, Klose G, Cosimi AB. Effective treatment of lymphedema of the extremities. Arch Surg. 1998;133(4):452\u20138. https:\/\/doi.org\/10.1001\/archsurg.133.4.452 Accessed 18 May 2022.","journal-title":"Arch Surg"},{"issue":"11","key":"388_CR21","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1001\/jamadermatol.2015.1895","volume":"151","author":"P Karaca-Mandic","year":"2015","unstructured":"Karaca-Mandic P, Hirsch AT, Rockson SG, Ridner SH. The cutaneous, net clinical, and health economic benefits of advanced pneumatic compression devices in patients with lymphedema. JAMA Dermatol. 2015;151(11):1187\u201393. https:\/\/doi.org\/10.1001\/jamadermatol.2015.1895 Accessed 18 May 2022.","journal-title":"JAMA Dermatol"},{"key":"388_CR22","doi-asserted-by":"publisher","unstructured":"Burian EA, Karlsmark T, Franks PJ, Keeley V, Qu\u00e9r\u00e9 I, Moffatt CJ. Cellulitis in chronic oedema of the lower leg: an international cross-sectional study. Br J Dermatol. 2021(185):110\u20138. https:\/\/doi.org\/10.1111\/bjd.19803 Accessed 18 May 2022.","DOI":"10.1111\/bjd.19803"},{"key":"388_CR23","unstructured":"Virginia special advisory commission on mandated health insurance benefits. Report of the special advisory commission on mandated health insurance benefits, house bill 383, mandated coverage of lymphedema, commonwealth of Virginia, Richmond, 2003. Available at https:\/\/rga.lis.virginia.gov\/search\/?query=RD15+2003. Accessed 26 Oct 2021."},{"key":"388_CR24","first-page":"CHBRP 05","volume-title":"Analysis of Assembly Bill 213 Health Care Coverage for Lymphedema - A Report to the 2005\u20132006","author":"California Health Benefits Review Program","year":"2005","unstructured":"California Health Benefits Review Program. Analysis of Assembly Bill 213 Health Care Coverage for Lymphedema - A Report to the 2005\u20132006: California Legislature; 2005. p. CHBRP 05\u20133. http:\/\/analyses.chbrp.com\/document\/view.php?id=166. Accessed 26 Oct 2021"},{"key":"388_CR25","unstructured":"Maryland Insurance Administration Lymphedema Workgroup Report, Al Redmer, Jr. Commissioner, 2018. https:\/\/insurance.maryland.gov\/Consumer\/Appeals%20and%20Grievances%20Reports\/Lymphedema-Workgroup-Report.pdf. Accessed 4 Jul 2022."},{"key":"388_CR26","unstructured":"Virginia House Bill No. 1737, \u201cA bill \u2026 relating to health insurance coverage for lymphedema\u201d by Delegate Leo C Wardrup, Jr. 2003. Available from https:\/\/lis.virginia.gov\/cgi-bin\/legp604.exe?031+ful+HB1737E. Accessed 26 Oct 2021."},{"key":"388_CR27","unstructured":"Virginia, State Corporation Commission Series. Report of the State Corporation Commission to the Governor and the General Assembly of Virginia: The Financial Impact of Mandated Health Insurance Benefits and Providers Pursuant to Section 38.2\u20133419.1 of the Code of Virginia: [year] Reporting Period. Reports are listed for the reporting years covered in Table 1, and are available at the Virginia Department of Insurance website at https:\/\/rga.lis.virginia.gov\/search\/by searching the report year and report number from Table 1 Accessed 26 Oct 2021."},{"key":"388_CR28","unstructured":"Virginia State Corporation Commission Bureau of Insurance. Administrative Code 14VAC5\u2013190-80:1 APPENDIX A. FORM MB-1 INSTRUCTIONS AND INFORMATION. (Was replaced in 2014 by an on-line Form 190-A). http:\/\/leg1.state.va.us\/cgi-bin\/legp504.exe?000+reg+14VAC5-190-9998. Accessed 26 Oct 2021."},{"key":"388_CR29","unstructured":"Virginia State Corporation Commission Bureau of Insurance. CPT and ICD-9-CM Codes to be used in filling out Forms MB-1 and 190-A for reporting costs of mandated benefits may be found on the Commonwealth of Virginia State Corporation Commission Bureau of Insurance web site at https:\/\/scc.virginia.gov\/boi\/co\/health\/mandben.aspx. Accessed 26 Oct 2021."},{"key":"388_CR30","volume-title":"Mitigating the loss of private insurance with public coverage for the Under-65 population: 2008 to 2012","author":"U.S. Department of Commerce Economics and Statistics Administration U.S. CENSUS BUREAU","year":"2013","unstructured":"U.S. Department of Commerce Economics and Statistics Administration U.S. CENSUS BUREAU. In: Rodean J, editor. Mitigating the loss of private insurance with public coverage for the Under-65 population: 2008 to 2012; 2013. https:\/\/www2.census.gov\/library\/publications\/2013\/acs\/acsbr12-11.pdf. Accessed 10 Jul 2022."},{"key":"388_CR31","unstructured":"Haislmaier EF. Health care consolidation and competition after PPACA \u2013 testimony before committee on the judiciary subcommittee on intellectual property, Competition and the Internet, United States House of Representatives, 2012.\u00a0https:\/\/republicans-judiciary.house.gov\/wp-content\/uploads\/2016\/02\/Haislmaier-05182012.pdf. Accessed 16 July 2022."},{"key":"388_CR32","unstructured":"Weiss R. \u201cMeasuring the Cost of a Lymphedema Treatment Mandate - 5 Years of Experience in the Commonwealth of Virginia (Revised December 2009)\u201d http:\/\/www.lymphactivist.org\/virginia_mandate.php. Accessed 26 Oct 2021."},{"key":"388_CR33","first-page":"27","volume":"46","author":"NL Stout","year":"2013","unstructured":"Stout NL, Weiss R, Feldman JL, Stewart BR, Armer JM, Cormier JN, et al. A systematic review of care delivery models and economic analyses in lymphedema: health policy impact (2004\u20132011). Lymphology. 2013;46:27\u201341 https:\/\/pubmed.ncbi.nlm.nih.gov\/23930439\/. Accessed 18 May 2022.","journal-title":"Lymphology"},{"key":"388_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13561-016-0117-3","volume":"6","author":"R Weiss","year":"2016","unstructured":"Weiss R. Cost of a lymphedema treatment mandate-10 years of experience in the Commonwealth of Virginia. Health Econ Rev. 2016;6:42. https:\/\/doi.org\/10.1186\/s13561-016-0117-3https:\/\/healtheconomicsreview.biomedcentral.com\/articles\/10.1186\/s13561-016-0117-3 [An Erratum to this article has been published in Health Economics Review 19 Oct 2016 6:47]. Accessed 18 May 2022.","journal-title":"Health Econ Rev"}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-022-00388-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13561-022-00388-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-022-00388-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T13:04:25Z","timestamp":1658581465000},"score":1,"resource":{"primary":{"URL":"https:\/\/healtheconomicsreview.biomedcentral.com\/articles\/10.1186\/s13561-022-00388-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,23]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["388"],"URL":"https:\/\/doi.org\/10.1186\/s13561-022-00388-6","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,23]]},"assertion":[{"value":"5 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declares that he has no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}